Indivior PLC (INDV)
INDV Stock Price Chart
Explore Indivior PLC interactive price chart. Choose custom timeframes to analyze INDV price movements and trends.
INDV Company Profile
Discover essential business fundamentals and corporate details for Indivior PLC (INDV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
29 Dec 2014
Employees
1.03K
Website
https://www.indivior.comCEO
Joseph J. Ciaffoni
Description
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
INDV Financial Timeline
Browse a chronological timeline of Indivior PLC corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 22 Apr 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 23 Oct 2025
EPS estimate is $0.36.
Earnings released on 31 Jul 2025
EPS came in at $0.51 surpassing the estimated $0.26 by +96.15%, while revenue for the quarter reached $302.00M , beating expectations by +18.32%.
Earnings released on 24 Apr 2025
EPS came in at $0.41 surpassing the estimated $0.22 by +86.36%, while revenue for the quarter reached $266.00M , beating expectations by +9.78%.
Earnings released on 20 Feb 2025
EPS came in at $0.32 matching the estimated $0.32, while revenue for the quarter reached $299.00M , beating expectations by +24.51%.
Earnings released on 24 Oct 2024
EPS came in at $0.54 surpassing the estimated $0.31 by +74.19%, while revenue for the quarter reached $307.00M , beating expectations by +17.88%.
Earnings released on 25 Jul 2024
EPS came in at $0.44 surpassing the estimated $0.40 by +10.00%, while revenue for the quarter reached $299.61M , beating expectations by +3.54%.
Earnings released on 25 Apr 2024
EPS came in at $0.37 falling short of the estimated $0.42 by -11.90%, while revenue for the quarter reached $282.74M , missing expectations by -5.68%.
Earnings released on 22 Feb 2024
EPS came in at $0.43 surpassing the estimated $0.28 by +53.57%, while revenue for the quarter reached $300.65M , beating expectations by +8.93%.
Earnings released on 9 Nov 2023
EPS came in at $0.34 surpassing the estimated $0.30 by +13.33%, while revenue for the quarter reached $261.20M , missing expectations by -3.44%.
Earnings released on 27 Jul 2023
EPS came in at $0.39 surpassing the estimated $0.22 by +77.27%, while revenue for the quarter reached $279.85M , beating expectations by +9.74%.
Earnings released on 27 Apr 2023
EPS came in at $0.40 , while revenue for the quarter reached $256.80M , missing expectations by -15.15%.
Earnings released on 30 Dec 2022
EPS came in at -$1.38 , while revenue for the quarter reached $249.52M , beating expectations by +11.89%.
Stock split effective on 17 Oct 2022
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 10 Oct 2022
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 29 Sept 2022
EPS came in at $0.27 , while revenue for the quarter reached $220.24M , beating expectations by +1.49%.
Earnings released on 29 Jun 2022
EPS came in at $0.33 , while revenue for the quarter reached $214.44M .
Earnings released on 30 Mar 2022
EPS came in at $0.27 , while revenue for the quarter reached $202.72M , missing expectations by -7.43%.
Earnings released on 30 Dec 2021
EPS came in at $0.25 , while revenue for the quarter reached $222.67M .
INDV Stock Performance
Access detailed INDV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.